This cross-disease validation strengthens the hypothesis that CIRBP dysregulation represents a conserved pathogenic mechanism in autoimmune disorders, potentially serving as a novel therapeutic target for MG management. The gene discussed is CIRBP; the disease is myasthenia gravis.